Sexual and Reproductive Health

5. MANAGEMENT OF ERECTILE DYSFUNCTION

5.1. Definition and classification

Erectile dysfunction is defined as the persistent inability to attain and maintain an erection sufficient to permit satisfactory sexual performance [245]. Erectile dysfunction may affect psychosocial health and have a significant impact on the QoL of patients and their partner’s [197,246-248]. Erectile dysfunction is commonly classified into three groups based on aetiology: organic, psychogenic and mixed ED. However, this classification should be used with caution as most cases are actually of mixed aetiology. Therefore, it has been suggested to use the terms “primary organic” or “primary psychogenic”.

5.2. Risk factors

Erectile dysfunction is a complex medical issue with several known causes, including vascular, hormonal, neurologic, and psychological dysfunctions and is associated with chronic health conditions [249]. An association with numerous risk factors including age, diabetes mellitus, dyslipidaemia, hypertension, CVD, obesity, MetS, hyperhomocysteinemia, lack of exercise, smoking and drug use has been reported [247,250-261]. In addition, a number of therapeutic agents for CVD have been shown to have a detrimental effect on erectile function (EF), whereas newer drugs have exhibited a neutral or even beneficial effect [253,262,263]. Other reported risk factors include atrial fibrillation, hyperthyroidism, vitamin D and folic acid deficiency, hyperuricemia, depression and anxiety disorders, chronic kidney and rheumatic disease, COPD, migraine, inflammatory bowel disease, osteoporosis and sleep disorders [258,264-277]. In addition, a growing body of evidence has demonstrated an association between the onset of new ED in men who have had COVID-19 [278-281].

Erectile dysfunction is also frequently associated with other urological conditions and procedures including LUTS/BPH and surgery for LUTS/BPH [282-284], chronic pelvic pain syndrome (CPPS) and chronic prostatitis [285], bladder pain syndrome/interstitial cystitis [286], premature ejaculation [287] and urethroplasty surgery for posterior urethral strictures [288].

5.3. Pathophysiology

The pathophysiology of ED may be vasculogenic, neurogenic, anatomical, hormonal, drug-induced and/or psychogenic (Table 5.1) [289]. In most cases, numerous pathophysiological pathways can co-exist and may all negatively impact EF.

Table 5.1: Pathophysiology of ED [289]

GnRH = gonadotropin-releasing hormone; 5-ARIs = 5α-reductase inhibitors.
*A symmetry analysis showed that cardiovascular drugs do not strongly affect the risk of subsequently being prescribed anti-erectogenic drug. The analysis only assessed the short-term risk [290]

5.3.1. Pelvic surgery and prostate cancer treatment

Pelvic surgery, especially for oncological disease (e.g., radical prostatectomy (RP) [291], radical cystectomy [292] and colorectal surgery [293]), may have a negative impact on EF and overall sexual health. Surgery resulting in damage of the neurovascular bundles, that control the complex mechanism of the cavernous erectile response, may result in ED, although nerve-sparing approaches have been adopted over the last few decades. To date only the surgical treatment of PCa has enough scientific evidence supporting its potential pathophysiological association with ED [294-296]. However, even non-surgical treatments of PCa (i.e., radiotherapy, or brachytherapy) can be associated with ED [294,297,298].

The ProtecT trial randomised 1,643 patients to active treatment (RP or RT) or active monitoring for localised PCa and assessed sexual function, including EF, using the EPIC-26 instrument [278]. At baseline, 67% of men reported erections firm enough for sexual intercourse. At six-year follow-up assessment this fell to 30% in the active monitoring group, 27%% in the RT group and 17% in the RP group, respectively. In a RCT comparing low- to intermediate-risk PCa patients treated with either surgery or RT (without ADT), the sexual function scores of EPIC-26 were significantly higher for men receiving RT at two years post-treatment [299].

Radical prostatectomy for the treatment of clinically localised intermediate- or high-risk PCa is a widely performed procedure. Research has shown that 25-75% of men experience post-RP ED [279,280,295]. Conversely, the rate of unassisted post-operative EF recovery ranges between 20 and 25% in most studies. These rates have not substantially improved or changed over the past two decades, despite growing attention to post-surgical rehabilitation protocols and refinement of surgical techniques [280,281,300]. Overall, patient age, baseline EF and surgical volume, with the subsequent ability to preserve the neurovascular bundles, are the main factors in promoting the highest rates of post-operative EF [279,296,301,302]. Regardless of the surgical technique, surgeons’ experience clearly impacts on post-operative EF outcome [303]. Surgical approach may also affect post-RP EF, but the current evidence is conflicting with one systematic review reporting a significant advantage in favour of RARP compared to open retropubic RP for twelve-month potency rates [304] and two RCTs reporting only a small improvement in EF for RARP or no different in EF between techniques [305,306].

Erectile dysfunction is also a common problem after both external beam radiation therapy (EBRT) and brachytherapy for PCa. A systematic review and meta-analysis including men treated with EBRT (65%), brachytherapy (31%) or both (4%) showed that the post-treatment prevalence of ED was 34% at one year and 57% at 5.5 years, respectively [307,308]. Similar findings have been reported for stereotactic radiotherapy with 26-55% of previously sexually functioning patients reporting ED at five years [309].

Recently other modalities have emerged as potential therapeutic options in patients with clinically-localised PCa, including high-intensity focused US (HIFU), cryo-therapeutic ablation of the prostate (cryotherapy), focal padeliporfin-based vascular-targeted photodynamic therapy and focal RT by brachytherapy or CyberKnife^®. All these approaches have been reported to have a less-negative impact on EF with many studies reporting a complete recovery at one-year follow-up [310].

5.3.2. Summary of evidence on the epidemiology/aetiology/pathophysiology of ED

5.4. Diagnostic evaluation (basic work-up)

5.4.1. Medical and sexual history

The first step in evaluating ED is always a detailed medical and sexual history of patients and, when available, their partners [311]. Figure 5.1 lists the minimal diagnostic evaluation (basic work-up) in patients with ED.

A detailed description should be made of the rigidity and duration of both sexually stimulated and morning erections and of problems with sexual desire, arousal, ejaculation, and orgasm [312-314]. Validated questionnaires, such as the IIEF [315] or its short version (i.e., Sexual Health Inventory for Men; SHIM) [316], help to assess the different sexual function domains (i.e., sexual desire, EF, orgasmic function, intercourse satisfaction, and overall satisfaction), as well as the potential impact of a specific treatment modality. Similarly, structured interviews allow the identification and quantification of the different underlying factors affecting EF [317].

Psychometric analyses also support the use of the Erectile Hardness Score (EHS) for the assessment of penile rigidity in practice and in clinical trials research [318]. Patients should always be screened for symptoms of possible hypogonadism, including decreased libido and energy, and fatigue (see Table 3.3: Specific symptoms associated with LOH).

5.4.2. Physical examination

Every patient must be given a physical examination focused on the genitourinary, endocrine, vascular and neurological systems [319,320]. A physical examination may reveal unsuspected diagnoses, such as Peyronie’s disease, pre-malignant or malignant genital lesions, prostatic enlargement or irregularity/nodularity, or signs and symptoms suggestive of hypogonadism (see Table 3.3: Specific symptoms associated with LOH).

Blood pressure and heart rate should be measured if they have not been assessed in the previous three to six months. Likewise, either BMI calculation or waist circumference measurement should be undertaken to assess patients for comorbid conditions (e.g., MetS).

5.4.3. Laboratory testing

Patients should undergo a fasting blood glucose or haemoglobin A1c and lipid profile measurement if they have not been assessed in the previous twelve months. Hormonal tests should include early morning total testosterone in a fasting state. The bio-available or calculated-free testosterone values may sometimes be needed to corroborate total testosterone measurements (see sections 3.2.1 and 3.4.1) [321]. Additional laboratory tests may be considered in selected patients with specific signs and associated symptoms (e.g., total PSA [322], PRL and LH [323]). Although physical examination and laboratory evaluation of most men with ED may not reveal the exact diagnosis, clinical and biochemical evaluation presents an opportunity to identify comorbid conditions [320].

Figure 5.1: Minimal diagnostic evaluation (basic work-up) in patients with ED

ED = erectile dysfunction; IIEF = International Index of Erectile Function.

5.4.4. Cardiovascular system and sexual activity: the patient at risk

Patients who seek treatment for sexual dysfunction have a high prevalence of CVDs. Erectile dysfunction significantly increases the risk of CVD, coronary heart disease, stroke, atrial fibrillation, cardiovascular and all-cause mortality [324]. Longitudinal data from an observational population-based study of 965 men without CVD showed that younger men (especially those < 50 years) with transient and persistent ED have an increased Framingham CVD risk [325]. Therefore, ED should be considered a precursor of CVD, and more severe and longer standing ED yields greater risk. Erectile dysfunction can improve the sensitivity of screening for asymptomatic CVD in men with or without diabetes [326-328].

Over time, the Princeton Consensus (Expert Panel) Conferences were dedicated to optimising sexual function and preserving cardiovascular health [329-333]. The current EAU Guidelines on the diagnosis and treatment of men with ED have been adapted from the recommendations from the Princeton Consensus conferences on sexual dysfunction and cardiac risk published in 2024 [334].

The Princeton Consensus Conference IV aimed to critically evaluate the current evidence for the relationship between ED and CV health, to update the CV work-up in the ED patient, to reassess when and how to treat ED patients with known CVD, and to reassess the accuracy and relevance of previous Princeton management algorithms [334,335]. Accordingly, the Princeton Consensus Conference IV recommended the use of the 2019 American College of Cardiology/American Heart Association atherosclerotic CVD (ASCVD) risk score for all men undergoing evaluation for predominantly vasculogenic ED [336]. As a whole, the ASCVD risk assessment score utilises the Pooled Cohort Equations (PCE), which is based on age; sex; ethnicity; total cholesterol and HDL-cholesterol concentrations; systolic blood pressure; and whether the patient is receiving treatment for hypertension, has diabetes, or smokes [336]. The ASCVD provides an estimate of the patient’s risk of a major CV event within the next 10 years categorised as follows: low risk < 5%; borderline risk 5% to < 7.5%; intermediate risk ≥ 7.5% to < 20%; and high risk ≥ 20% [334,337].

In this context, since men aged 40 to 60 years can have their cardiac risk significantly underestimated with this tool alone, the Expert Panel Consensus from the Princeton Conference IV recommended to use the widely available non-contrast-enhanced cardiac computed tomography to measure coronary artery calcium (CAC) scores for all men in the borderline to intermediate ASCVD risk category as the most sensitive and specific marker of subclinical CAD [334]. Therefore, the Princeton Consensus Conference IV ended using the CAC score as the single strongest predictor of CVD risk and the concept of it being ideal to guide clinical recommendations.

Accordingly, the proposed cardiovascular work-up for patients presenting with ED now relies on a flowchart which largely considers the 10-year ASCVD risk calculation (Figure 5.2). Moreover, a specific flowchart is also dedicated to ED patients with overt CV symptoms and/or CVD (Figure 5.3). This algorithm aims to estimate the CV risk associated with sexual activity in patients with ED and known CVD (i.e., the full range of CV disorders, including but not limited to ischemic disorders, arrhythmias, and cardiac output pathology). The goal is to identify the risks related to the likelihood of mortal or morbid events during or shortly after sex. The updated recommendations from the Princeton Consensus Conference IV also extend to include the appropriateness of treatment with PDE5Is among low-risk patients currently using or who have easy access to nitrates that they might use [334].

Overall, the flowcharts proposed by the Princeton Consensus Panel IV, including the CAC scoring, should always be considered taking into account local expertise, availability of test and cost effectiveness. They should be adapted to the European context and tailored to account for the heterogeneity of patients' clinical profiles.

Figure 5.2: Cardiovascular risk assessment of ED patient with no overt disease or cardiac symptoms (based on IV Princeton Consensus) [334] 

Reproduced with permission from Kloner et al., 2024
ED = erectile dysfunction; CVD = cardiovascular disease; ASCVD = Atherosclerotic Cardiovascular Disease;CAC = coronary artery calcium.

Figure 5.3. Management of ED in men with overt CV symptoms and/or CVD (based on IV Princeton Consensus) [334]

Reproduced with permission from Kloner et al., 2024
*Low-risk patients: Patients for whom sexual activity does not represent significant cardiac risk. These patients can generally perform exercise of modest intensity without symptoms and include successfully revascularized individuals, patients with asymptomatic controlled hypertension, those with mild valvular disease, and patients with left ventricular dysfunction/heart failure (NYHA classes I and II) who achieved 5 METS without ischemia on recent exercise testing.
**Intermediate-risk or indeterminable (or indeterminate) risk patients: Patients with mild or moderate stable angina pectoris, past myocardial infarction (MI) (2-8 weeks) without intervention awaiting exercise electrocardiography, congestive heart failure patients (NYHA class III), and noncardiac sequelae of atherosclerotic disease (e.g., peripheral arterial disease, history of stroke or transient ischemic attack). In this setting, further examination using exercise stress testing is required for indeterminate-risk patients before resuming sexual activity. If patients cannot complete a standard exercise test (owing to a disabling condition such as arthritis), a chemical stress test with echocardiography or nuclear imaging can be performed. Moreover, patients with suspected atherosclerotic disease may need additional testing using CAC, carotid intima-media thickness or the ankle-brachial index that may be helpful in reclassifying to high- or low-risk categories.
***High-risk patients: Patients with severe cardiac conditions or unstable enough to pose a significant risk with sexual activity. Overall, most men are moderately or severely symptomatic. Common high-risk profiles include unstable or refractory angina pectoris, uncontrolled hypertension, congestive heart failure (NYHA class IV), recent MI without intervention (< 2 weeks), high-risk arrhythmia (exercise-induced ventricular tachycardia, implantable cardioverter-defibrillator with frequent shocks, and poorly controlled atrial fibrillation).
ED = erectile dysfunction; PDE5Is = Phosphodiesterase 5 Inhibitors.

5.5. Diagnostic Evaluation (advanced work-up)

Most patients with ED can be managed based on their medical and sexual history; conversely, some patients may need specific diagnostic tests (Table 5.2).

5.5.1. Nocturnal penile tumescence and rigidity test

The nocturnal penile tumescence and rigidity (NPTR) test applies nocturnal monitoring devices that measure the number of erectile episodes, tumescence (circumference change by strain gauges), maximal penile rigidity, and duration of nocturnal erections. The NPTR assessment should be performed on at least two separate nights. A functional erectile mechanism is indicated by an erectile event of at least 60% rigidity recorded on the tip of the penis that lasts for ≥ 10 minutes [338]. Nocturnal penile tumescence and rigidity monitoring is an approach for objectively differentiating between organic and psychogenic ED (patients with psychogenic ED usually have normal findings in the NPTR test). However, there are still limitations to NPTR namely the true correlation between NPTR and a sex-related erection, the definition used to establish ED as well as the many potential confounding factors (e.g., situational, age, depression, sleep-related content) may limit its routine use for diagnostic purposes [338,339].

5.5.2. Intracavernous injection test

The intracavernous injection test gives limited information about vascular status. A positive test is a rigid erectile response (unable to bend the penis) that appears within 10 minutes after the intracavernous injection and lasts for 30 minutes [340]. Overall, the test per se is inconclusive as a diagnostic procedure and a duplex Doppler study of the penis should be requested, if clinically warranted.

5.5.3. Dynamic duplex ultrasound of the penis

Dynamic duplex ultrasound (US) of the penis is a second-level diagnostic test that specifically studies the haemodynamic pathophysiology of EF. Therefore, in clinical practice, it is usually applied in those conditions in which a potential vasculogenic aetiology of ED (e.g., diabetes mellitus, multiple concomitant CV risk factors and/or overt peripheral vascular disease, renal transplantation and poor responders to oral therapy) is suspected. Peak systolic blood flow > 30 cm/s, end-diastolic velocity < 3 cm/s and resistance index > 0.8 are considered normal [341,342]. Recent data suggest that duplex scanning as a haemodynamic study may be better at tailoring therapy for ED, such as for low-intensity shock wave treatment (LI-SWT) in men with vasculogenic ED [343]. Further vascular investigation is unnecessary if a duplex US examination is normal. However, it has limitations with regards to the standardised metrics for the haemodynamic parameters utilised, its diagnostic accuracy is challenged by false positive diagnosis due to confounding factors (e.g. anxiety, low vasoactive agent dosage) and its added value to the intracavernous injection test is still unclear [344-347]. Measures such as audiovisual sexual stimulation, high-dosage alprostadil or combination of vasoactive and/or oral agents can help improve its accuracy [348-350].

5.5.4. Arteriography and dynamic infusion cavernosometry or cavernosography

Pudendal arteriography should be performed only in patients who are being considered for penile revascularisation [351]. Currently, dynamic infusion cavernosometry or cavernosography are infrequently used diagnostic modalities for the assessment of venogenic ED and the concept of venogenic ED has been questioned. Computed tomography cavernosography is an emerging diagnostic modality providing detailed anatomical information that may aid in diagnosing and planning treatment for ED [352].

5.5.5. Psychopathological and psychosocial assessment

Mental health issues and psychological distress are frequently comorbid with ED [353]. This is most evident for depression and anxiety related disorders, but may also include transitory states of altered mood (i.e., dysfunctional affective states resulting from a specific life stressor or crisis) [270,354,355]. Relationship factors, including lack of satisfaction with the partner, poor sexual relationships, length of the relationship, or feeling emotionally disconnected from the partner during sex, have been related to erectile difficulties and dysfunction [354,356,357]. In contrast, intimacy was found to be a protective factor in ED [259,358]. Additionally, the cognitive factors underpinning organic and non-organic ED (i.e., all dysfunctional thinking styles and expectations about sexuality, poor self-esteem and cognitive distraction from erotic cues) must also be assessed.

Psychosexual assessment in ED cases include a clinical interview considering all the previous topics [359]. Also, self-reported measures are frequently used within the psychosocial context [360]. A growing amount of data suggests that men who have sex with men (MSM) presenting specific psychological risks associated with erectile capability regarding anal sex [361]. Therefore, professionals must tailor their assessment in the context of sexual minorities.

Figure 5.4: Psychopathological and psychosocial assessment

Table 5.2: Indications for specific diagnostic tests for ED and the specific diagnostic tests

5.5.6. Summary of evidence and recommendations for diagnostic evaluation of ED

5.6. Treatment of erectile dysfunction

The Guidelines Panel have developed a comprehensive therapeutic and decision-making algorithm (Figure 5.5) for treating ED. The treatment algorithm was developed as an alternative to the traditional three-tier concept, to support personalised treatment tailored to individual patients, according to invasiveness, tolerability and effectiveness of the different therapeutic options and patients’ expectations. In this context, patients should be fully counselled with respect to all available treatment modalities.

The majority of men with ED are not treated with cause-specific therapeutic options. This results in a tailored treatment strategy that depends on invasiveness, efficacy, safety and costs, as well as patient preference [362]; therefore, physician-patient dialogue is essential throughout the management of ED. A systematic review has shown a consistent discontinuation rate for all available ED treatment options [363]. This highlights the importance of clinicians understanding patient’s beliefs about ED treatment, therapeutic ineffectiveness, adverse effects, quality of intimate relationships and treatment costs all of which were shown to be the most prevalent barriers to treatment use [363].

Figure 5.5: Management algorithm for erectile dysfunctionED = erectile dysfunction; PDE5Is = phosphodiesterase type 5 inhibitors; Li-SWT = low-intensity shockwave therapy.

5.6.1. Patient education

Educational intervention is often the first approach to sexual complaints and consists of informing patients about the psychological and physiological processes involved in the individual’s sexual response, in ways the patient can understand. This baseline approach has been shown to favour sexual satisfaction in men with ED [364]. Accordingly, consultation with the patient should include a discussion of the expectations and needs of the patient’s and his sexual partner. It should also review the patient’s and partner’s understanding of ED and the results of diagnostic tests, and provide a rationale for treatment selection [362].

5.6.2. Modifiable risk factors

Erectile dysfunction may be associated with modifiable or reversible risk factors, including lifestyle or drug-related factors [365]. These factors may be modified either before, or at the same time as, specific therapies are used. Likewise, ED may be associated with concomitant and underlying conditions (e.g., endocrine disorders and metabolic disorders such as diabetes, and some cardiovascular problems such as hypertension) which should always be well-controlled as the first step of any ED treatment [366]. Overall, several studies have shown that lifestyle modifications including physical activity especially aerobic exercise, weight loss including via bariatric surgery and treatment for CVD risk factors may be of help in improving sexual function in men with ED [263,365,367-371]. Regarding the use of statins, although previous meta-analyses had demonstrated an improvement in ED [372,373].

5.6.3. Phosphodiesterase type 5 inhibitors

Four potent selective PDE5Is have been approved by the EMA for treatment of ED [374]. The efficacy of all four PD5EIs in almost every subgroup of patients with ED has been successfully established [374-377]. Efficacy is defined as an erection, with rigidity, sufficient for satisfactory intercourse [366]. In addition, adverse events for the four PDE5Is are generally mild and self-limiting [378-382]. The pharmacokinetic data for all four PDE5Is and their associated adverse events are presented in Tables 5.3 and 5.4, respectively. Choice of PDE5I depends on frequency of intercourse and the patient’s personal experience. Two meta-analyses demonstrated that ED patients who prioritise high efficacy should use sildenafil 50 mg whereas those who optimise tolerability should initially use tadalafil 10 mg [375,383]. It is important to highlight that a meta-analysis investigating the placebo responses in patients treated with PDE5Is showed a significant improvement of ED, especially among men with ED-related post-traumatic stress disorder [384].

5.6.3.1. Sildenafil

Sildenafil is administered in doses of 25, 50 and 100 mg. The recommended starting dose is 50 mg and should be adapted according to the patient’s response and adverse effects [385]. The window of effectiveness ranges from 30-60 minutes after administration [385] up to 12 hours [386]. In a 24-week dose-response study, improved erections were reported by 56%, 77% and 84% of general ED patients taking 25, 50 and 100 mg sildenafil, respectively, compared to 25% of men taking placebo [387]. Sildenafil also significantly improved patient scores for IIEF, sexual encounter profile question 2 (SEP2), SEP question 3 (SEP3), General Assessment Questionnaire (GAQ) and treatment satisfaction [387]. Furthermore, an orally disintegrating tablet (ODT) of sildenafil citrate at doses of 25, 50, 75 and 100 mg has been developed, mainly for patients who have difficulty swallowing solid dosage forms [388]. Likewise, a sildenafil oral suspension treatment has been developed, with clinically relevant results [2000,2001].

5.6.3.2. Tadalafil

Tadalafil is administered in on-demand doses of 10 and 20 mg or a daily dose of 5 mg. The recommended on-demand starting dose is 10 mg and should be adapted according to the patient’s response and adverse effects [389,390]. The window of effectiveness ranges from 30 minutes after administration (peak efficacy after approximately 2 hours) up to 36 hours [389]. In a 12-week dose-response study improved erections were reported by 67% and 81% of men with ED taking 10 and 20 mg tadalafil, respectively, compared to 35% of men taking placebo [389]. Tadalafil has also been shown to have a net clinical benefit in the short-term on ejaculatory and orgasmic functions in ED patients [391].

Data have also shown that 40% of men aged > 45 years were combined responders for ED and LUTS/BPH when treated with tadalafil 5 mg once daily, with symptom improvement after 12 weeks [392]. Therefore, its use may be considered in both patients with ED only and in patients also complaining of concomitant LUTS, and wishing to benefit from a single therapy [393].

5.6.3.3. Vardenafil

Vardenafil is administered in on-demand doses of 5, 10 and 20 mg. The recommended starting dose is 10 mg and should be adapted according to the patient’s response and adverse effects [380]. Vardenafil is effective from 30 minutes after administration [394], with one of three patients achieving satisfactory erections within 15 minutes of ingestion [395]. In a 12-week dose-response study, improved erections were reported by 66%, 76% and 80% of men with ED taking 5, 10 and 20 mg vardenafil, respectively, compared with 30% of men taking placebo [380,396]. Vardenafil significantly improved patient scores for IIEF, SEP2, SEP3, and GAQ and treatment satisfaction. An orodispersable tablet (ODT) formulation of vardenafil has also been released [396]. The efficacy of vardenafil ODT has been demonstrated in several RCTs and did not seem to differ from the regular formulation [397-399].

5.6.3.4. Avanafil

Avanafil is administered in on-demand doses of 50, 100 and 200 mg [381]. The recommended starting dose is 100 mg taken as needed 15-30 minutes before sexual activity and the dose may be adapted according to efficacy and tolerability [381,382,400]. In a general ED population the mean percentage of successful sexual attempts resulting in intercourse were 47%, 58% and 59% for the 50, 100 and 200 mg groups, respectively, as compared with 28% for the placebo group [381,382]. A meta-analysis confirmed that avanafil had comparable efficacy with sildenafil, vardenafil and tadalafil [401].

5.6.3.5. Continuous use of PDE5Is

According to the EMA, a once-daily regimen with tadalafil 2.5 or 5 mg may be considered suitable, based on patients’ choice and physicians’ judgement. In these patients, the recommended dose is 5 mg, taken once daily at approximately the same time each day. Tadalafil, 5 mg once daily, provides an alternative to on-demand tadalafil for couples who prefer spontaneous rather than scheduled sexual activities or who anticipate frequent sexual activity, with the advantage that dosing and sexual activity no longer need to be linked. regardless of the type of ED population, there is no clinically significant difference between a tadalafil treatment administered with continuous (once daily) vs. on-demand tadalafil [402]. Overall, treatment with tadalafil 5 mg once daily in men complaining of ED of various severities is well-tolerated and effective [403] and may improve EF among men who have a partial response to on-demand PDE5I therapy [404]. The appropriateness of the continuous use of a daily regimen should be re-assessed periodically [403,405].

Table 5.3: Pharmacokinetics data for PDE5Is EMA approved for the treatment of ED*

* Fasted state, higher recommended dose. Data adapted from EMA statements on product characteristics.
Cmax = maximal concentration; Tmax = time-to-maximum plasma concentration; T1/2 = plasma elimination halftime; AUC = area under curve or serum concentration-time curve.

Table 5.4: Common adverse events of the four PDE5Is currently EMA-approved to treat ED*

* Adapted from EMA statements on product characteristics.

5.6.3.6. Safety concerns for PDE5Is

5.6.3.6.1. Cardiovascular safety

No RCTs or open-label studies have demonstrated an increase in myocardial infarction (MI) rates in patients receiving PDE5Is. In contrast, an observational study demonstrated that in men with stable CAD, treatment with PDE5I is associated with lower risks of death, MI, heart failure, and revascularization compared with alprostadil treatment [406]. None of the PDE5Is have an adverse effect on total exercise time or time-to-ischaemia during exercise testing in men with stable angina [374,407]. This EAU Guidelines panel agrees to maintain the recommendations provided by the 3rd Princeton Consensus Panel in terms of prescription of all PDE5Is in patients with CVD or in those with high CV risk [330-332].

5.6.3.6.2. Contraindications for the concomitant use of organic nitrates and nicorandil

An absolute contraindication to PDE5Is is the concomitant use of any form of organic nitrate or NO donors including recreational use of amyl nitrite or nitrate (poppers). Concomitant use results in cGMP accumulation and unpredictable falls in blood pressure and symptoms of hypotension [408-411]. Concurrent use of nicorandil and PDE5Is is contraindicated due to the potential of the nitric oxide donating properties of nicorandil to increase cGMP levels [412].

5.6.3.6.3. Antihypertensive drugs

Co-administration of PDE5Is with antihypertensive agents may result in small additive decreases in blood pressure, which are usually minor [330]. In general, the adverse event profile of a PDE5I is not worsened by a background of antihypertensive medication, even when the patient is taking several antihypertensive agents [413-415].

5.6.3.6.4. Interactions with α-blockers

Tadalafil 5 mg is currently the only licensed drug for the treatment of both ED and LUTS demonstrating overall good efficacy in relieving urinary symptoms and improving EF [393]. Therefore, treatment with tadalafil 5 mg should be considered in patients suffering from mild to moderate LUTS associated with ED either alone or in combination with α-blockers. Conversely, as both drugs are vasodilators a certain degree of caution has been observed for combination therapy with PDE5Is and alpha-blockers due to the potential cumulative effects on blood pressure described in some studies [386,395,416]. However, a meta-analysis concluded that a concomitant treatment with α-blockers [both non-uroselective (e.g., terazosin and doxazosin) and uro-selective (e.g., alfuzosin, tamsulosin and silodosin) and PDE5Is may produce changes in haemodynamic parameters, but it does not increase the rate of adverse events due to hypotension [416]. Therefore, there is no current limitation in the simultaneous use of α-blockers and PDE5I.

5.6.3.7. Management of non- or poor-responders to PDE5Is

The management of non-responders depends upon identifying the underlying cause [417]. Clinicians should begin by ensuring that the medication has been properly prescribed, is being correctly used by the patient and that the patient has been using a licensed medication. Absorption of sildenafil, vardenafil and avanafil can be delayed by high-fat meals [418-420]. Timing is important and patients may be waiting either too short or too long after the medication before attempting sexual intercourse. Studies suggest that patient education can help salvage an apparent non-responder to a PDE5I [417,421-424]. After emphasising the importance of dose, timing, and sexual stimulation to the patient, EF can be effectively restored following re-administration of the relevant PDE5I [417,421,422].

Studies have demonstrated that hypogonadal patients not responding to PDE5Is may improve their response to PDE5Is after initiating testosterone therapy [87,366,425]. Therefore, if diagnostic criteria suggestive for testosterone deficiency are present, testosterone therapy may be more appropriate even in ED patients [3,87].

Limited data suggest that some patients might respond better to one PDE5I than to another [426], raising the possibility that, despite an identical mode of action, switching to a different PDE5I may be beneficial. However, no evidence for this has been reported in the available RCTs [427,428].

In refractory, complex, or difficult-to-treat cases of ED a combination therapy should be considered as a first-line approach. Although the available data are still limited, there are several strategies that can be considered including: PDE5Is with antioxidant agents, LI-SWT or a vacuum erection device (VED) [429]; daily tadalafil with an on-demand short-acting PDE5I (such as sildenafil) [430]; Li-SWT with VED [431]; and PDE5Is with topical alprostadil [432].

5.6.3.8. Topical/Intraurethral alprostadil

The vasoactive agent alprostadil can be administered inside the urethra with two different formulations. The first delivery method is topical, using a cream that includes a permeation enhancer to facilitate absorption of alprostadil (200 and 300 μg) via the urethral meatus [433,434]. Clinical data are still limited. Significant improvement compared to placebo was recorded for IIEF-EF domain score, SEP2 and SEP3 in a broad range of patients with mild-to-severe ED [435]. Adverse effects include penile erythema, penile burning, and pain that usually resolve within two hours of application. Topical alprostadil (VITAROSTM) at a dose of 300 μg is available in some European countries. Recently, a randomised cross-over clinical trial has shown that, compared to the standard administration route, direct delivery within the urethral meatus can increase efficacy and confidence among patients, without increasing adverse effects [436].

The second delivery method is by intra-urethral insertion of a specific formulation of alprostadil (125-1000 μg) in a medicated pellet (MUSE™) [229]. Erections sufficient for intercourse are achieved in 30-65.9% of patients. In clinical practice, it is recommended that intra-urethral alprostadil is initiated at a dose of 500 μg, as it has a higher efficacy than the 250 μg dose, with minimal differences with regards to adverse events. In case of unsatisfactory clinical response, the dose can be increased to 1000 μg [437-439]. Overall, the most common adverse events are local pain (29-41%) and dizziness with possible hypotension (1.9-14%). Penile fibrosis and priapism are rare (< 1%). Urethral bleeding (5%) and urinary tract infections (0.2%) are adverse events related to the mode of administration.

Efficacy rates are significantly lower than for intracavernous pharmacotherapy [440], with 30% adherence to long-term therapy. Intraurethral pharmacotherapy provides an alternative to intracavernous injections in patients who prefer a less-invasive, although less-efficacious treatment.

5.6.4. Psychosocial intervention and therapy

Psychosocial interventions including different modalities (e.g., sexual skills training, marital therapy, psychosexual education) [364], and Cognitive and Behavioural Therapy (CBT - group or couple format), even if conducted online, are recommended [359,441]. Cognitive and Behaviour Therapy is aimed at altering dysfunctional cognitive and behavioural patterns influencing ED, and increasing adjustment during the course of the disorder. The CBT approach combined with medical treatment for ED has received empirical support and is considered an optimal procedure [442].

5.6.5. Hormonal treatment

When clinically indicated, testosterone therapy (intramuscular, transdermal, or oral) can be considered for men with low or low-normal testosterone levels and concomitant problems with sexual desire, EF and dissatisfaction derived from intercourse and overall sex life (see Section 3.4 for a comprehensive discussion of testosterone therapy) [443,444], even in patients with a history of CVD [445].

5.6.6. Vacuum erection devices

Published data report that efficacy, in terms of erections satisfactory for intercourse, is as high as 90%, regardless of the cause of ED and satisfaction rates range between 27% and 94% [446,447]. Long-term use of VEDs decreases to 50-64% after two years [448]. The most common adverse events include pain, inability to ejaculate, petechiae, bruising, and numbness [447]. Serious adverse events (skin necrosis) can be avoided if patients remove the constriction ring within 30 minutes. Vacuum erection devices are contraindicated in patients with bleeding disorders or on anticoagulant therapy [449,450]. Vacuum erection devices may be the treatment of choice in well-informed older patients with infrequent sexual intercourse and comorbidity requiring non-invasive, drug-free management of ED [446,447,451].

5.6.7. Intracavernous injections therapy

Intracavernous administration of vasoactive drugs was the first medical treatment introduced for ED [424,452]. Patients may be offered intracavernous injections at every stage of a tailored treatment work-up.

5.6.7.1. Alprostadil

Alprostadil (Caverject^TM, Edex/Viridal^TM) was the first and only drug approved for intracavernous treatment of ED [424,453]. Intracavernous alprostadil is most efficacious as a monotherapy at a dose of 5-40 μg (40 μg may be offered off label in some European countries). The erection appears after 5-15 minutes and lasts according to the dose injected, but with significant heterogeneity among patients. An office-training programme is required for patients to learn the injection technique. Efficacy rates for intracavernous alprostadil of > 70% have been found in the general ED population, as well as in patient subgroups (e.g., men with diabetes or CVD), with reported satisfaction rates of 87-93.5% in patients and 86-90.3% in partners after the injections [424,452]. Complications of intracavernous alprostadil include penile pain (50% of patients reported pain only after 11% of total injections), excessively prolonged and undesired erections (5%), priapism (1%), and fibrosis (2%) [424,452,454]. Pain is usually self-limited after prolonged use and it can be alleviated with the addition of sodium bicarbonate or local anaesthesia [424,452,455]. Cavernosal fibrosis usually clears within a few months after temporary discontinuation of the injection programme. However, tunical fibrosis suggests early onset of Peyronie’s disease and may indicate the need to discontinue intracavernous injections indefinitely. Systemic adverse effects are uncommon. The most common is mild hypotension, especially when using higher doses. In a large population study including 16,548 men with a history of ischemic CVD, those treated with alprostadil had higher risk of a further cardiovascular event as compared to those receiving PDE5Is [406]. Contraindications include men with a history of hypersensitivity to alprostadil, men at risk of priapism, and men with bleeding disorders. Despite these favourable data, drop-out rates of 41-68% have been reported for intracavernous pharmacotherapy [424,452,456,457], with most discontinuations occurring within the first two to three months. Careful counselling of patients during the office-training phase as well as close follow-up are important in addressing patient withdrawal from an intracavernous injection programme [458-460].

5.6.7.2. Other vasoactive intracavernous treatments

Table 5.5 details the available intracavernous injection therapies (compounds and characteristics). Combination therapy enables a patient to take advantage of the different modes of action of the drugs being used, as well as alleviating adverse effects by using lower doses of each drug.

• Papaverine (20-80 mg) was the first oral drug used for intracavernous injections. It is most commonly used in combination therapy because of its high incidence of adverse effects as monotherapy. Papaverine is currently not licensed for treatment of ED.
• Phentolamine has been used in combination therapy to increase efficacy. As monotherapy, it produces a poor erectile response. Phentolamine is currently not licensed for treatment of ED.
• Limited data support the use of other drugs, such as vasoactive intestinal peptide (VIP), NO donors (linsidomine), forskolin, potassium channel openers, moxisylyte or calcitonin gene-related peptide, usually combined with the main drugs [461,462]. Most combinations are not standardised and some drugs have limited availability worldwide.
• Bimix, (papaverine 7.5-45 mg plus phentolamine 0.25-1.5 mg) and Trimix (papaverine 8-16 mg plus phentolamine 0.2-0.4 mg plus alprostadil 10-20 μg), have been widely used with improved efficacy rates, although they have never been licensed for ED [463,464]. Trimix has the highest efficacy rates, reaching 92%; this combination has similar adverse effects as alprostadil monotherapy, but a lower incidence of penile pain due to lower doses of alprostadil. However, fibrosis is more common (5-10%) when papaverine is used (depending on total dose).
• Invicorp^TM: Vasoactive intestinal peptide (25 μg) plus phentolamine mesylate (1-2 mg Invicorp), is a combination of two active components with complementary modes of action. Clinical studies have shown that the combination is effective for intracavernous injections in > 80% of men with ED, including those who have failed to respond to other therapies and, unlike existing intracavernous therapies, is associated with a low incidence of penile pain and a virtually negligible risk of priapism [465].

Overall, despite high efficacy rates, 5-10% of patients do not respond to combination intracavernous injections.

Table 5.5: Intracavernous injection therapy - compounds and characteristics

5.6.8. Innovative treatment modalities

There are currently several potential novel treatment modalities for ED. Most of these therapeutic approaches require further investigation in large-scale, blinded, placebo-controlled randomised studies to achieve adequate evidence-based and clinically-reliable recommendation grades [466-471].

5.6.8.1. Regenerative medicine therapies

5.6.8.1.1. Shockwave therapy

The use of LI-SWT has been increasingly proposed as a treatment for vasculogenic ED over the last decade, and it’s the only currently marketed treatment that might offer a cure, which is the most desired outcome for most men suffering from ED [343,472-479].

Overall, several single-arm trials have shown a beneficial effect of LI-SWT on patient-reported EF. However, there are significant differences in reported outcome measures due to the heterogeneity among shockwave generators, type of shockwaves delivered (focal vs. radical), set-up parameters and treatment protocols [480,481]. In a trial trying to assess the best treatment parameters, no significant differences were observed between various energy flux density levels; although, a 0.10 mJ/mm² seems to perform slightly better than lower energies [482]. The majority of trials have been conducted with generators delivering focal shockwaves [343,480,481]. On the other hand, a RCT using radial wave therapy showed no difference was found in terms of IIEF-EF and EHS score between treatment and placebo groups [483].

Despite this most studies have suggested that LI-SWT can significantly increase IIEF and EHS scores in patients with mild vasculogenic ED, although this improvement appears modest and the rates of patients reporting a satisfactory improvement range between 40-80% [343,480]. Few studies have shown an improvement in penile haemodynamic parameters after LI-SWT, but the clinical meaning of this improvement remains unclear [480,484]. Likewise, data suggest that LI-SWT could ameliorate erection quality even in patients with severe ED who are either PDE5Is non-responders [477,485,486] or inadequate responders [487], thus reducing the immediate need for more invasive treatments. Treatment effect appears to be clinically evident starting from one to three months after treatment completion, with a subsequent progressive decrease of the achieved benefit in terms of EF over time, although some effects could be still detected up to five years after treatment [480,482,488]. Data from RCTs suggests that even better results could be achieved by combining LI-SWT with other treatments such as a VED in men with T2DM [431] or daily tadalafil [489,490].

Findings from a recent meta-analysis showed that LI-ESWT has a positive effect on early recovery of EF in the context of penile rehabilitation of ED after RP. However, the authors clearly outlined that the level of evidence was low; therefore, careful interpretation of the results is required [491-493].

5.6.8.1.2. Platelet-Rich Plasma

Intracavernous injection of platelet-rich plasma (PRP) has been investigated in several prospective and retrospective trials [494-500]. The regenerative effect of PRP is deemed to be exerted through the high concentrations of platelets containing several growth factors including VEGF, EGF, IGF-1, PDGF and FGF [501]. These factors may be responsible for angiogenesis stimulation and stem cell recruitment [501].

In the first RCT investigated the effect of intracavernous injection of PRP for ED, 60 patients with mild to moderate vasculogenic ED were randomised to receive two injections of 10 mL PRP (n = 30) or placebo (n = 30) [500]. At 1, 3 and 6-month follow-up, the rate of patients reporting minimal clinically important difference (MCID) in the IIEF-EF score was significantly higher in the treatment group, with 69% achieving MCID 6 months after PRP vs. 27% in the placebo group (p < 0.001). IIEF-EF scores improved by a mean of 2.7 points at 1-month and 3.9 points at 6-month assessment after treatment. Regarding safety, no haemorrhagic events or other side effects were reported [500].

A prospective randomised, double-blind, placebo-controlled study was carried out on 109 patients, aged 45-65 years, with mild to moderate ED, following cessation of any ED treatment [502]. At 1, 3 and 6 months after PRP injections, patients in PRP group had a significant improvement compared to placebo in terms of IIEF-EF, SEP2 and SEP3. Moreover, at 6-month post-treatment follow-up, 70% patients achieved a MCID in the PRP group compared to 16% in the placebo group [502]. Even more recently, a further prospective, randomized, double-blind, placebo control study on a relatively small cohort of mild to moderate ED patients who have been treated with two PRP injections separated by 1 month showed that the treatment is safe, but the authors did not find any difference in efficacy between PRP and placebo [503]. Of clinical relevance, patients were allowed to continue PDE5Is during the study [503]. A meta-analysis of the above mentioned RCTs reported a mean improvement in IIEF-EF score with PRP vs. placebo of 3.21 [95%CI: 1.82; 4.60] 6 months after treatment [504].

As a whole, despite a number of promising results that have been obtained for the treatment of primary organic ED in terms of both efficacy and safety of PRP, the available evidence is still insufficient to provide a recommendation regarding the use of PRP for ED treatment in clinical practice [505]. In this context, there is heterogeneity among studies in terms of timing and dosing regimens, with no consensus regarding the optimal activation method and platelet concentration for each PRP injection, and the need to measure qualitative and quantitative composition of growth factors and cytokines [505,506]. Therefore, intracavernous injection of PRP should be used only in a clinical trial setting, as larger trials are needed to confirm original findings and define the efficacy and safety of PRP for ED.

5.6.8.1.3. Stem-cells

The use of stem cells as a regenerative treatment for ED is currently under investigation. A systematic review summarising the results of 18 phase I and II clinical trials reported a large heterogeneity in terms of the type of stem cells used, treatment protocols and patients’ characteristics [507]. The overall number of included patients was 373 and the results confirmed the safety of intracavernous injection of stem cells. No definitive conclusions can be drawn in terms of efficacy given that only four small trials were placebo-controlled and their findings were conflicting. To date, data are still insufficient for providing a clinical recommendation.

5.6.8.2. Botulinum Neurotoxin

Botulinum Neurotoxin A (BoNT-A) has been investigated as a possible ED treatment [508]. Two RCTs have investigated the effect of BoNT-A for the treatment of patients with ED who were non-responders to PDE5Is or ICI pro-erectile drugs [509,510]. One trial randomised 70 patients with ED refractory to PDE5Is to receive a single ICI of 100 UI of BoNT-A or saline [509]. Patients in both groups were instructed to keep using on-demand high-dose PDE5Is. The RCT showed an improvement in EHS and PSV at two weeks post-treatment. At six weeks the treatment group showed a 5 points improvement in the SHIM score vs. no improvement in the placebo group, with 53% of patients reporting an erection hard enough for vaginal penetration [509]. The second trial randomised 176 patients, all non-responders to PDE5Is or ICI trimix, to three treatment groups: BoNT-A 100 UI; BoNT-A 50 UI; or placebo [510]. A significant improvement in SHIM, EHS and SEP scores was reported in both treatment groups with a maximum response rate being reacted three months after treatment. Overall, the RCT showed that up to 40% of patients were able to resume satisfactory sexual activity after treatment [510]. Both trials reported only mild local side-effects with no systemic complications.

Other single-arm, non-controlled studies have confirmed these findings [511,512]; therefore, showing a promising role for BoNT-A in the treatment of patients who are non-responders to well-established ED therapies. However, at present no recommendation for its use in clinical practice can be provided as larger trials are needed to confirm original findings and define the efficacy and safety of BoNT-A for ED.

5.6.9. Herbal medicine and natural supplements

In recent years there has been an exponential growth in the market of medicinal herbs and natural supplements for the treatment of ED, but with very little available evidence of robust scientific data to support their efficacy and safety. A Cochrane review showed that ginseng may only have trivial effects on erectile function or satisfaction with intercourse compared to placebo when assessed using validated tools [513]. A meta-analysis including 18 trials comparing the effect of antioxidants alone or in combination with PDE5Is vs. placebo or PDE5Is alone showed a small but significant positive effect of L-arginine with a mean increase in IIEF-EF of 2.74 (95%CI 1.67,3.81) compared to placebo but no difference in terms of sexual satisfaction score [514]. Similar results were reported for antioxidants alone including folic acid, myoinositol, vitamin-E, L-carnitine, nicotinic acid, pine bark extract, transresveratrol, L-citrulline and ginseng. However, this small improvement may not be perceived as significant by patients. In another meta-analysis the combination of PDE5Is plus antioxidants (including: propionyl-L-carnitine, acetyl-L-carnitine; L-arginine, folic acid, and trans-resveratrol) was associated with better EF improvement compared to PDE5Is alone [429]. Overall, these data suggest that antioxidant supplements and herbal compounds alone or in combination with PDE5Is may have a small positive effect on EF, although further studies are needed to assess the clinical significance of these findings.

5.6.10. Erectile dysfunction after radical prostatectomy

Overall, urologists should have enhanced awareness of how to approach patients directly about their ED and sexual dysfunction following RP and actively offer them treatment options [515]. Use of pro-erectile drugs following RP is important in achieving post-operative EF and to allow patients to resume sexual activity. Several trials have shown improvements in EF after RP in patients receiving drugs (any therapeutic or prophylactic) for ED. Early compared with delayed EF treatment affects the natural recovery time for EF [516], although there is limited data to support any specific regimen, which is either optimal for penile rehabilitation or may result in the achievement of spontaneous, non-pharmacologically assisted erections [296,517,518]. Data from a small pilot RCT showed that perioperative rehabilitation with PDE5Is may lead to better EF recovery compared to post-operative rehabilitation [519]. However, there is no evidence that penile rehabilitation itself increases the chances of spontaneous recovery of EF in men following nerve-sparing RP (NSRP) [518]. The currently available therapeutic armamentarium follows the treatment algorithm for ED, which is shown in Figure 5.2.

In this context, PDE5Is have been considered as the first-line therapy in patients who have undergone NS surgery, regardless of the surgical technique used [296,301]. Several clinical parameters have been identified as potential predictors of PDE5Is outcomes in men undergoing RP, i.e., patient age, baseline EF, and quality of NS technique are key factors in preserving post-RP EF [301,304,520].

A Cochrane review analysing data from eight RCTs showed that scheduled PDE5Is may have little or no effect on short-term (up to 12 months) self-reported potency when compared to placebo or no treatment [521]. In this study, a daily PDE5I made little to no difference in short- and long-term EF. The authors conclude that penile rehabilitation strategies using PDE5I following RP do not increase self-reported EF compared to on-demand use. Conversely, an updated meta-analysis including 22 trials comparing 16 different rehabilitation protocols, showed that daily administration of sildenafil 100 mg was the most effective strategy to recover EF after RP [522].

Intracavernous injections and penile implants had been suggested as second- and third-line treatments, respectively, when oral PDE5Is are not adequately effective or not suitable for post-operative patients [296,523]. A meta-analysis showed that the early use of VED has an excellent therapeutic effect on post-RP patients and no serious adverse effects, therefore it should be considered as a therapeutic alternative [524]. Findings from two network meta-analyses showed that combination therapy with VED and PDE5is offers clear advantages over monotherapy, even in post-RP patients; therefore, this combined approach should be considered in the clinical management of ED after RP [525]. A novel penile traction device yielded positive results compared to no treatment in preserving penile length after RP [526].

Findings from a systematic review had suggested that pelvic floor muscle training (PFMT) combined with bio-feedback is a promising alternative to pharmacological treatments, although there is a need for future well-powered, rigorously designed RCTs to draw strong conclusions [527].

5.6.11. Surgical management

5.6.11.1. Surgery for post-traumatic arteriogenic ED

In young patients with pelvic or perineal trauma, surgical penile revascularisation has a 60-70% long-term success rate [450,528]. The stenosis must be confirmed by penile pharmaco-arteriography. Corporeal veno-occlusive dysfunction is a contraindication to revascularisation and must be excluded by dynamic infusion cavernosometry or cavernosography.

5.6.11.2. Venous ligation surgery

Venous ligation surgery for veno-occlusive dysfunction is no longer recommended because of poor long-term results [528].

5.6.11.2.1. Penile prostheses

The surgical implantation of a penile prosthesis may be considered in patients who i) are not suitable for different pharmacotherapies or prefer a definitive therapy; and, ii) do not respond to other treatment modalities [529].

The two currently available classes of penile implants include inflatable (two- and three-piece) and semi-rigid devices (malleable, mechanical and soft flexible) [301,530-533]. There are currently no head-to-head studies comparing the different manufacturers’ implants, demonstrating superiority of one implant type over another [534]. Patients may prefer the three-piece inflatable devices due to the more “natural” erections obtained, although no prospective RCTs have compared satisfaction rates with both types of implants. The two-piece inflatable prosthesis can be a viable option among patients who are deemed at high-risk of complications with reservoir placements (e.g., previous abdominal surgery). Semi-rigid prostheses result in a firm penis, which may be manually placed in an erect or flaccid state and offer the advantage of a simple implant technique, as well as easy use for the patient [301,530-532]. Conversely, they can have the disadvantage of unnatural persistent erection and reduced concealability [532,535]. They may also be an option in men with limited manual dexterity.

There are two main surgical approaches for penile prosthesis implantation: peno-scrotal and infrapubic [531,532,535,536]. A systematic review comparing the satisfaction and complication rates of the different surgical approaches has shown that there is no specific advantage between the two, but rather it is recommended that surgeons have knowledge of both techniques and are capable of tailoring the incision strategy for complex cases [537]. Regardless of the indication, prosthesis implantation has one of the highest satisfaction rates (92-100% in patients and 91-95% in partners) among the treatment options for ED with appropriate counselling [301,530,531,538-546]. Focused psychosexual counselling may improve sexuality and sexual well-being in both patients and their partners after penile implant surgery [547]. There is sufficient evidence to recommend this approach in patients who do not respond to less-invasive treatments due to its high efficacy, safety and satisfaction rate [548].

The two main complications of penile prosthesis implantation are mechanical failure and infection. Several technical modifications of the most commonly used three-piece prostheses (e.g., AMS 700CX/CXR™ and Titan Zero degree™) resulted in mechanical failure rates of < 5% after 5 years of follow-up [530,549,550]. A meta-analysis showed implant durability or survival rates of 93.3% at 1 year, 91.0% at 3 years, 87.2% at 5 years, 76.8% at 10 years, 63.7% at 15 years, and 52.9% at 20 years [551]. Careful surgical techniques with appropriate antibiotic prophylaxis against Gram-positive and negative bacteria reduced infection rates to 2-3% with primary implantation in low-risk patients and in high-volume centres [552-555]. The infection rate may be further reduced to 1-2% by implanting an antibiotic-impregnated prosthesis (AMS Inhibizone™) or hydrophilic-coated prosthesis (Coloplast Titan™) [530,552,556-559]. Methods that appear to decrease infection rates include using coated prostheses and strictly adhering to surgical techniques and protocols that avoid prolonged wound exposure and minimise skin contact (i.e., no-touch technique). Techniques that might prevent penile prostheses infection but lack definitive evidence include the use of prolonged post-operative antibiotics (> 24 hours), shaving with clippers, and preparation with chlorhexidine-alcohol [560,561]. Identification and pre-treatment of patients who are colonised with nasal Staphylococcus aureus with mupirocin and chlorhexidine prior to surgery has been shown to reduce the incidence of post-operative surgical site infection from 4.4% to 0.9% RCT [562].

A large database-study has shown that diabetes mellitus is a risk factor for penile prostheses infection, highlighting the need for optimal patient selection [667]. Unfortunately, there are no RCTs determining the ideal and/or correct threshold of glycated haemoglobin that is acceptable prior to implant surgery in diabetic patients [563]. A large-cohort, multicentre, retrospective analysis in men with diabetes who received a Coloplast Titan™ implant demonstrated that vancomycin plus gentamicin was the most efficacious combination of antibiotics used for implants dipping in terms of preventing postoperative infection and subsequent explantation and revision [564]. A retrospective analysis of a large insurance claim database in the US, showed that hypogonadism was independently associated with infection of the implant [565]. Patients with spinal cord injury had higher risk of complications with up to 16% of cases reporting prosthesis infection in published series [566].

Prosthetic infection requires removal of the prosthesis and antibiotic administration. Alternatively, removal of the infected device with immediate salvage and replacement with a new prosthesis has been described using a wash-out protocol with successful salvages achieved in > 80% of cases [553,567-569]. An absolute recommendation on how to proceed after explantation in this setting cannot be given and must be focused on the pros and cons of salvage therapy after full consultation with the patient.

Besides infection and mechanical failure, impending implant erosion involving the distal corpora, urethra, or glans can occur in 1-6% of cases after surgery [570]. Moreover, non-infectious reservoir complications including injury to pelvic structures such as bladder, bowel, and blood vessels have been described [571]. Similarly, glans ischaemia and necrosis have been reported in about 1.5% of patients [570,572]. Risk factors for these serious complications are higher in those patients with significant vascular impairment, such as patients with diabetes, or who have undergone concomitant lengthening procedures.

For penile prostheses models available on the market please see Appendix 3 online supplementary evidence (https://uroweb.org/guidelines/sexual-and-reproductive-health/publications-appendices).

5.6.12. Summary of evidence and recommendations for treatment of ED

5.7. Follow-up

Follow-up is important in order to assess efficacy and safety of the treatment provided. It is also essential to assess patient satisfaction since successful treatment for ED goes beyond efficacy and safety. Physicians must be aware that there is no single treatment that fits all patients or all situations as described in detail in the previous section.